Welcome to our dedicated page for Scynexis SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing SCYNEXIS’s clinical updates, royalty agreements, and dilution clauses across dozens of forms can feel like navigating a lab notebook written in legal code. Each 10-K details multi-arm Phase 3 trial data, while an 8-K may quietly announce a material safety issue or new partnership. Stock Titan surfaces every line the moment it hits EDGAR, so SCYNEXIS SEC filings are explained simply—no pharmacology degree required.
Our AI engine distills the 250-page SCYNEXIS annual report 10-K simplified, highlights cash runway assumptions, and flags risk disclosures about antifungal resistance. Need the latest SCYNEXIS quarterly earnings report 10-Q filing? We tag revenue from ibrexafungerp launches and compare R&D spend quarter-over-quarter. Curious about SCYNEXIS Form 4 insider transactions real-time? Receive instant alerts on executive stock movements, then dive into our charted trend analysis. From SCYNEXIS proxy statement executive compensation to every SCYNEXIS 8-K material events explained, you’ll know where trial milestones, ATM sales, or licensing royalties show up—and why they matter.
Investors use Stock Titan to:
- Track SCYNEXIS insider trading Form 4 transactions before FDA catalysts
- Compare drug-development costs via our SCYNEXIS earnings report filing analysis
- Save hours understanding SCYNEXIS SEC documents with AI through concise bullet summaries and red-flag alerts
SCYNEXIS (SCYX) reported Q3 2025 results. License revenue was $334,000, down from $660,000 a year ago. Operating expenses fell to $8.7 million, led by lower R&D at $5.5 million and SG&A of $3.3 million. The company posted a net loss of $8.6 million, or $0.17 per share, including a $0.6 million loss from warrant fair value adjustments.
Cash, cash equivalents, and short-term investments totaled $37.9 million as of September 30, 2025. Convertible notes were repaid at maturity in March 2025, reducing current debt to zero. A $10.0 million license receivable is on the balance sheet tied to the GSK collaboration.
After quarter-end, SCYNEXIS and GSK signed a binding memorandum of understanding under which SCYNEXIS will wind down the MARIO study and receive one-time payments totaling $24.8 million. Other potential milestones and royalties under the GSK license remain unchanged. The company also disclosed a Nasdaq minimum bid price notice received on June 20, 2025, with a compliance period through December 17, 2025.
SCYNEXIS (SCYX) reported an insider transaction on a Form 4. On 10/17/2025, a company Chief Executive Officer and Director acquired 32,500 shares of common stock at $0.76 per share. Following this trade, the insider’s beneficial ownership stands at 853,098 shares, held directly.
The filing notes this total includes 4,000 shares acquired under the 2014 Employee Stock Purchase Plan on 09/05/2025.
SCYNEXIS (SCYX) entered a binding memorandum of understanding with GSK to amend their exclusive license, resolving the prior disagreement over the Phase 3 MARIO study of ibrexafungerp. SCYNEXIS will promptly wind down and terminate the MARIO study and will receive $22 million from GSK, plus an additional $2.3 million in connection with the wind-down and termination activities. SCYNEXIS will not receive additional milestone payments specifically tied to MARIO.
GSK reiterated its commitment to the broader collaboration, including commercialization of BREXAFEMME (ibrexafungerp tablets) for VVC and rVVC. SCYNEXIS continues to progress the transfer of the BREXAFEMME NDA to GSK by the end of 2025. GSK anticipates initiating FDA interactions in 2026 to discuss a U.S. relaunch for VVC and rVVC. Other potential milestones and royalties under the exclusive license remain unchanged.
Federated Hermes, Inc. and related Reporting Persons report beneficial ownership of 5,116,598 shares of Scynexis Inc. common stock, representing
SCYNEXIS, Inc. reported that the FDA lifted the clinical hold on ibrexafungerp on April 24, 2025, and dosing in the Phase 3 MARIO study resumed in May 2025, prompting the company to bill a $10.0 million development milestone to GSK in Q2 2025. The company is disputing GSK’s April 28, 2025 notice that purported to terminate the MARIO study and deny further milestone payments, including a $30.0 million milestone tied to study resumption.
Financially, SCYNEXIS recognized $1.364 million in license revenue for the quarter and reported a net loss of $6.885 million for Q2 2025 ($12.276 million year-to-date). Cash and investments totaled $46.5 million at June 30, 2025 (down from $75.1 million at year-end), the March 2019 convertible notes were repaid $14.0 million in March 2025, and the accumulated deficit was $388.8 million. The company received a Nasdaq deficiency notice on June 20, 2025 for a closing bid below $1.00 and has until December 17, 2025 to regain compliance. Ongoing securities class and derivative lawsuits remain pending.
FAQ
What is the current stock price of Scynexis (SCYX)?
What is the market cap of Scynexis (SCYX)?
